TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Delivery of Cardiovascular Preventive Care (IDOCC) Through Outreach Facilitation
Brief Summary: The aim of the proposed study is to implement and evaluate Outreach Facilitation as a means to increase the uptake of evidence-based practice for secondary prevention and management of patients with established CVD and cardiovascular risk factors, in primary care practices throughout the Champlain LHIN. This initiative centers on the use of an Outreach Facilitation Model, in which skilled health professionals known as facilitators (Practice Change Consultants) serve as an expert resource to primary care practices in three areas: a) practice performance assessment, feedback, and consensus building towards goal setting and implementation; b) clinical, technical, organizational resources and practical advice; and c) encouragement to face and move through the challenges associated with implementing system change.


Options:
A: Arm Label: Updated CHD risk profiles; Type: EXPERIMENTAL; Interventions: Behavioral: Updated CHD risk profiles | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Guidelines | Intervention Type: BEHAVIORAL; Name: Updated CHD risk profiles; Assigned to Arm(s): Updated CHD risk profiles | Intervention Type: BEHAVIORAL; Name: Guidelines; Assigned to Arm(s): Guidelines
B: Intervention Type: DEVICE; Name: Heart-to-Heart Decision Aid; Assigned to Arm(s): N/A
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Outreach Facilitation implementing elements of the Chronic Care Model | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outreach Facilitation implementing elements of the Chronic Care Model; Assigned to Arm(s): intervention
D: Arm Label: ATP III; Type: EXPERIMENTAL; Interventions: Behavioral: Palm-Pilot Intervention | Arm Label: JNC 7; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Palm-Pilot Intervention | Intervention Type: BEHAVIORAL; Name: Palm-Pilot Intervention; Assigned to Arm(s): ATP III, JNC 7

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Delivery of Cardiovascular Preventive Care (IDOCC) Through Outreach Facilitation
Brief Summary: The aim of the proposed study is to implement and evaluate Outreach Facilitation as a means to increase the uptake of evidence-based practice for secondary prevention and management of patients with established CVD and cardiovascular risk factors, in primary care practices throughout the Champlain LHIN. This initiative centers on the use of an Outreach Facilitation Model, in which skilled health professionals known as facilitators (Practice Change Consultants) serve as an expert resource to primary care practices in three areas: a) practice performance assessment, feedback, and consensus building towards goal setting and implementation; b) clinical, technical, organizational resources and practical advice; and c) encouragement to face and move through the challenges associated with implementing system change.


Options:
A: Arm Label: PRIME; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PRIME/mhGAP | Arm Label: PRIME+RESHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: RESHAPE, Behavioral: PRIME/mhGAP | Intervention Type: BEHAVIORAL; Name: RESHAPE; Assigned to Arm(s): PRIME+RESHAPE | Intervention Type: BEHAVIORAL; Name: PRIME/mhGAP; Assigned to Arm(s): PRIME, PRIME+RESHAPE
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Outreach Facilitation implementing elements of the Chronic Care Model | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outreach Facilitation implementing elements of the Chronic Care Model; Assigned to Arm(s): intervention
C: Arm Label: Direct & Digital; Type: OTHER; Interventions: Other: Digital Engagement, Other: Direct Engagement | Arm Label: Direct & Registry; Type: OTHER; Interventions: Other: Direct Engagement | Arm Label: Digital & Registry; Type: OTHER; Interventions: Other: Digital Engagement | Arm Label: Registry; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Digital Engagement; Assigned to Arm(s): Digital & Registry, Direct & Digital | Intervention Type: OTHER; Name: Direct Engagement; Assigned to Arm(s): Direct & Digital, Direct & Registry
D: Arm Label: Shared decision-making program; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making program | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Shared decision-making program; Assigned to Arm(s): Shared decision-making program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain: A Randomized Clinical Trial
Brief Summary: A pulmonary recruitment maneuver at the end of surgery reduced shoulder pain as well as nausea and vomiting after laparoscopic surgery.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Recruitment manouver | Intervention Type: PROCEDURE; Name: Recruitment manouver; Assigned to Arm(s): Intervention
B: Arm Label: Pulmonary recruitment maneuver; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary recruitment maneuver | Arm Label: Intraperitoneal normal saline infusion; Type: EXPERIMENTAL; Interventions: Procedure: Intraperitoneal normal saline infusion | Arm Label: combined group; Type: EXPERIMENTAL; Interventions: Procedure: combined group | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Pulmonary recruitment maneuver; Assigned to Arm(s): Pulmonary recruitment maneuver | Intervention Type: PROCEDURE; Name: Intraperitoneal normal saline infusion; Assigned to Arm(s): Intraperitoneal normal saline infusion | Intervention Type: PROCEDURE; Name: combined group; Assigned to Arm(s): combined group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Procedure: intervention | Arm Label: control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: intervention; Assigned to Arm(s): intervention
D: Arm Label: Deep neuromuscular blockade; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rocuronium | Arm Label: Moderate neuromuscular blockade; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rocuronium; Assigned to Arm(s): Deep neuromuscular blockade | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Moderate neuromuscular blockade

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial
Brief Summary: The purpose of this study is to determine whether simvastatin is effective in the improvement of IVF-ICSI outcome in Pcos patients.


Options:
A: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
B: Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIMVASTATIN | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: SIMVASTATIN | Intervention Type: DRUG; Name: SIMVASTATIN; Assigned to Arm(s): A, B
D: Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-arm, Open Label Multicenter Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of C.E.R.A. for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia
Brief Summary: This single arm study will assess the efficacy, safety and tolerability of monthly intravenous Mircera for the maintenance of hemoglobin levels in dialysis patients with chronic renal disease, currently receiving epoetin alfa or beta. Patients will receive monthly intravenous injections of Mircera at a starting dose of 120, 200 or 360 micrograms/month, depending on the dose of epoetin alfa or beta they were receiving in the week preceding study start. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: RO0503821 (C.E.R.A.), 1x/4weeks; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (C.E.R.A.), 1x/4weeks
B: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
C: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety
Brief Summary: The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical antipsychotic drug) compared with placebo in children or adolescents who have autism, and to evaluate the safety and tolerability of the drug for additional 26 weeks after the initial 6-week study period.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
B: Arm Label: Extended-release guanfacine; Type: EXPERIMENTAL; Interventions: Drug: extended-release guanfacine | Arm Label: Inactive placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Inactive placebo | Intervention Type: DRUG; Name: extended-release guanfacine; Assigned to Arm(s): Extended-release guanfacine
C: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety
Brief Summary: The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical antipsychotic drug) compared with placebo in children or adolescents who have autism, and to evaluate the safety and tolerability of the drug for additional 26 weeks after the initial 6-week study period.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
D: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety
Brief Summary: The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical antipsychotic drug) compared with placebo in children or adolescents who have autism, and to evaluate the safety and tolerability of the drug for additional 26 weeks after the initial 6-week study period.


Options:
A: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
B: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma
Brief Summary: This study will investigate the efficacy of weekly intravenous obinutuzumab \[GA101 (RO5072759)\] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Experimental: 1; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Arm Label: Placebo Comparator: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Experimental: 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 2
B: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Arm Label: Physicians' Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physicians' Choice | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab | Intervention Type: DRUG; Name: Physicians' Choice; Assigned to Arm(s): Physicians' Choice
C: Arm Label: Treatment (alemtuzumab, rituximab, fludarabine phosphate); Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab, Biological: rituximab, Drug: fludarabine phosphate | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate) | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate) | Intervention Type: DRUG; Name: fludarabine phosphate; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate)
D: Arm Label: Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: obinutuzumab (RO5072759) | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: rituximab | Intervention Type: DRUG; Name: obinutuzumab (RO5072759); Assigned to Arm(s): Obinutuzumab | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study Comparing Endovascular Repair Versus Conventional Repair for Ruptured Aorta-iliac Aneurysms
Brief Summary: The aim of this multicenter randomized trial is to compare the endovascular repair versus conventional repair for ruptured aorta-iliac aneurysms observed on CT scan in stable patients with suitable anatomy. The main awaited result is the significant reduction of the mortality of the conventional repair.


Options:
A: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1
D: Arm Label: 1; Type: OTHER; Interventions: Procedure: Endovascular repair | Arm Label: 2; Type: OTHER; Interventions: Procedure: Endovascular repair | Intervention Type: PROCEDURE; Name: Endovascular repair; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study
Brief Summary: To investigate using the drug gabapentin to relieve the intense pruritic sensation associated with chronic renal failure patients undergoing peritoneal dialysis.


Options:
A: Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): N/A
B: Arm Label: MT-9938 2.5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg | Arm Label: MT-9938 5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 5μg | Arm Label: MT-9938 10μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 10μg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 2.5μg; Assigned to Arm(s): MT-9938 2.5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 5μg; Assigned to Arm(s): MT-9938 5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 10μg; Assigned to Arm(s): MT-9938 10μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin 75mg daily for 12 weeks | Arm Label: fexofenadine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fexofenadine 60 mg daily for 12 weeks | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin 75mg daily for 12 weeks; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: fexofenadine 60 mg daily for 12 weeks; Assigned to Arm(s): fexofenadine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: turmeric; Type: EXPERIMENTAL; Interventions: Drug: turmeric | Arm Label: plasebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: turmeric; Assigned to Arm(s): turmeric | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): plasebo | Intervention Type: DRUG; Name: turmeric; Assigned to Arm(s): turmeric

Answer: A